PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 26, 2024Alimentary Pharmacology & Therapeutics23 citationsOpen Access

Branched‐chain amino acid supplementation does not improve measures of sarcopenia in cirrhosis: results of a randomised controlled trial

View Full Paper
PHPenelope HeyRHRudolf HoermannMSMarie Sinclair

Key Points

Key points are not available for this paper at this time.

Abstract

Sarcopenia is associated with adverse outcomes in cirrhosis. Branched-chain amino acids (BCAA) target several pathways that lead to muscle loss in this population.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hey et al. (2024) studied this question.

synapsesocial.com/papers/68e777acb6db6435876ecb86https://doi.org/10.1111/apt.17917
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit2005 · 844 citations
  2. 2Beta‐hydroxy‐beta‐methylbutyrate supplementation and skeletal muscle in healthy and muscle‐wasting conditions2017 · 284 citations
  3. 3The Analysis of Food Intake in Patients with Cirrhosis Waiting for Liver Transplantation: A Neglected Step in the Nutritional Assessment2019 · 33 citations
  4. 4Adding Branched-Chain Amino Acids to an Enhanced Standard-of-Care Treatment Improves Muscle Mass of Cirrhotic Patients With Sarcopenia: A Placebo-Controlled Trial2021 · 72 citations
  5. 5Development of a novel frailty index to predict mortality in patients with end‐stage liver disease2017 · 537 citations